A recent observational study showed that the rapid-acting insulin analog gluslisine was associated with a reduced incidence of macro- and microvascular events in patients with type 2 diabetes in comparison with human regular insulin [12]. This evidence concerns the gene INS and type 2 diabetes mellitus.